SCHEMBL2860220

SCHEMBL2860220

COc1cc(OC)c2nc(C(F)(F)F)cc(Cl)c2c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.41
▸ SMN1; SMN2 Q16637 3/20 0.41
▸ LMNA P02545 2/20 0.41
▸ POLB P06746 1/20 0.41
▸ RAD52 P43351 1/20 0.41
▸ PDE4B Q07343 5/20 0.40
▸ PDE4A P27815 3/20 0.40
▸ PDE4C Q08493 3/20 0.40
▸ PDE4D Q08499 3/20 0.40
▸ PDE11A Q9HCR9 1/20 0.40
▸ MEN1 O00255 3/20 0.39
▸ CYP1A2 P05177 2/20 0.39
▸ CYP3A4 P08684 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ CYP2D6 P10635 2/20 0.39
▸ CYP2C19 P33261 2/20 0.39
▸ ENPP3 O14638 1/20 0.39
▸ ENPP1 P22413 1/20 0.39
▸ JAK2 O60674 1/20 0.38
▸ NT5E P21589 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2859335 0.84 KMT2A (0.41) KMT2ASMN1; SMN2LMNAPOLBRAD52
SCHEMBL20521940 0.80 KMT2A (0.44) KMT2ASMN1; SMN2LMNAPOLBRAD52
SCHEMBL874733 0.79 NQO2 (0.48) SMN1; SMN2PDE4BPDE4APDE4CPDE4D
SCHEMBL11546200 0.78 MAPT (0.41) KMT2ASMN1; SMN2LMNAMEN1CYP3A4
SCHEMBL9428089 0.76 PDE4B (0.41) KMT2ASMN1; SMN2PDE4BPDE4APDE4C
SCHEMBL13135663 0.75 KDM4E (0.64) KMT2ASMN1; SMN2LMNAPOLBRAD52
SCHEMBL2848163 0.74 HTR6 (0.52) KMT2ASMN1; SMN2MEN1CYP1A2CYP3A4
SCHEMBL2709780 0.74 NT5E (0.60) KMT2ASMN1; SMN2LMNAPOLBRAD52
SCHEMBL27931127 0.72 KDM4E (0.44) KMT2ASMN1; SMN2MEN1CYP1A2CYP3A4
SCHEMBL30615186 0.71 KMT2A (0.42) KMT2ASMN1; SMN2LMNAPOLBRAD52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7790725-B2 Thiazolidine derivatives and medicinal use thereof MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-09-07 — — US disclosed
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORPORATION (JP) 2007-11-08 — — US disclosed
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof MITSUBISHI PHARMA CORPORATION (JP) 2004-12-23 — — US disclosed
EP-1426366-A1 THIAZOLIDINE DERIVATIVE AND MEDICINAL USE THEREOF Mitsubishi Pharma Corporation (JP) 2004-06-09 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070259880-A1 THIAZOLIDINE DERIVATIVES AND MEDICINAL USE THEREOF DPP4, DPP7, DPP3 KMT2A 1595/4885SMN1; SMN2 3494/4885LMNA 4632/4885
US-20040259883-A1 Thiazolidine derivative and medicinal use thereof DPP4, DPP7, DPP3 KMT2A 1883/4885SMN1; SMN2 2677/4885LMNA 4727/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback